Pres, CEO at Halozyme Therapeutics, Inc. Sells $6.44 million in Stock

Helen Torley, who serves as Pres, CEO at Halozyme Therapeutics, Inc. (HALO), sold 60,000 shares of the company's stock, according to a disclosure filed with the U.S. Securities and Exchange Commission.

The transaction was executed at a price of $107.28 per share, for a total value of approximately $6.44 million.

Insider transactions of this kind are publicly disclosed through Form 4 filings with the SEC, which must generally be submitted within two business days of the trade date.

Sales by insiders often reflect routine portfolio management or pre-scheduled trading plans rather than a view on the company's prospects.